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Background. The optimum strategy for stopping treatment with drugs that have different half-lives in a
combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated
drug concentrations in plasma, human immunodeficiency virus (HIV) load, and development of drug resistance
after a planned treatment interruption of a nonnucleoside reverse-transcriptase inhibitor (NNRTI)–containing
regimen in HIV type 1–infected children.
Methods. Children with viral loads !50 copies/mL and CD4 cell percentages 30% (for children aged 2–6
years) or CD4 cell percentages 25% and CD4 cell counts 500 cells/mL (for children aged 7–15 years) were
randomized to either a planned treatment interruption or to continuous therapy. In the planned treatment
interruption arm, either (1) treatment with nevirapine or efavirenz was stopped, and treatment with the remaining
drugs was continued for 7–14 days, or (2) nevirapine or efavirenz were replaced by a protease inhibitor, and all
drugs were stopped after 7–14 days. Sampling for determination of plasma drug concentrations, measurement of
viral load, and drug resistance testing was scheduled at day 0, day 7 (drug concentrations only), day 14, and day
28 after interruption of treatment with an NNRTI.
Results. Treatment with an NNRTI was interrupted for 35 children (20 were receiving nevirapine, and 15 were
receiving efavirenz). Median time from NNRTI cessation to stopping all drugs was 9 days (range, 6–15 days) for
nevirapine and 14 days (range, 6–18 days) for efavirenz. At 7 days, 1 (5%) of 19 and 4 (50%) of 8 children had
detectable nevirapine and efavirenz concentrations, respectively; efavirenz remained detectable in 3 (25%) of 12
children at 14 days. At 14 days, viral load was 50 copies/mL in 6 of 16 children interrupting treatment with
nevirapine (range, 52–7000 copies/mL) and in 2 of 12 children interrupting treatment with efavirenz (range, 120–
1600 copies/mL). No new NNRTI mutations were observed.
Conclusions. In children with virological suppression who experienced interruption of treatment with an
NNRTI, staggered or replacement stopping strategies for a median of 9 days for nevirapine and 14 days for efavirenz
were not associated with the selection of NNRTI resistance mutations.
Current antiretroviral treatment guidelines recommend
continuous HAART for the treatment of HIV infection
and AIDS; however, whether planned or unplanned,
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therapy is sometimes interrupted. Triple-combination
HAART regimens typically contain drugs with different
half-lives; therefore, stopping a HAART regimen may
lead to temporary functional monotherapy and, as viral
load rebounds, can potentially increase the risk of se-
lecting drug-resistant viruses [1].
Among the antiretroviral drug classes, nonnucleoside
a Members of the Paediatric European Network for Treatment of AIDS are listed
at the end of the text.
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reverse transcriptase inhibitors (NNRTIs) have the longest
plasma half-lives; 25–30 h for nevirapine [2] and 40–55 h for
efavirenz [3]. The majority of nucleoside reverse-transcriptase
inhibitors (NRTIs) and protease inhibitors have plasma half-
lives of !10 h. Thus, the risk of temporary functional mono-
therapy when simultaneously stopping all drugs in an NNRTI-
containing regimen is high, and because NNRTIs have a low
genetic barrier to within-class drug resistance, this situation
could potentially compromise the efficacy of future NNRTI-
containing regimens. Other drugs with low genetic barriers,
such as the NRTI lamivudine, may also be susceptible to the
development of resistance in this situation, especially because
its active moiety, the intracellular drug triphosphate, has a half-
life of ∼20 h [2].
In adults, several studies have examined the persistence of
NNRTI plasma drug concentrations after treatment interrup-
tion. Efavirenz plasma concentrations can persist for 14 days
after stopping therapy [3]. In contrast, at steady state, nevi-
rapine plasma concentrations did not persist 114 days after
treatment interruption [4], although after a single dose of ne-
virapine during labor for the prevention of mother-to-child
transmission of HIV, plasma concentrations have been detected
up to 21 days postpartum [5].
The impact of selecting NNRTI-resistant strains after treat-
ment interruption on subsequent NNRTI-based therapy has
been highlighted in the prevention of mother-to-child trans-
mission of HIV setting. HIV-infected women exposed to single-
dose nevirapine during labor were found to be less likely to
achieve virologic suppression after 6 months of postpartum
treatment with an NNRTI-based regimen, compared with no-
nexposed women [6]. Short-course, dual-NRTI treatment post-
partum (administered for 3–7 days) after administration of
single-dose nevirapine has been shown to reduce the risk of
selecting NNRTI-resistant strains [7], but the optimal choice
and duration of such treatment remains unknown.
To date, no pediatric data after NNRTI treatment interrup-
tion are available. Therefore, in the context of a pediatric phase
II exploratory planned treatment interruption (PTI) trial, we
describe plasma drug concentrations, viral rebound, and selec-
tion of HIV drug resistance mutations in children receiving an
NNRTI-based HAART regimen during the first PTI cycle in
the trial.
PATIENTS, MATERIALS, AND METHODS
Study population. All children were enrolled in the Paediatric
European Network for Treatment of AIDS (PENTA) 11: Treat-
ment Interruption in Children with Chronic HIV-Infection
Trial. PENTA-11 is an ongoing, open, randomized, phase II
exploratory trial evaluating the role of PTIs in the treatment
of HIV-infected children who have responded well to antiret-
roviral therapy (ISRCTN36694210; http://www.controlled-
trials.com). Children receiving stable HAART for at least 6
months with plasma HIV-1 RNA levels !50 copies/mL and a
CD4 cell percentage 30% (for children aged 2–6 years) or a
CD4 cell percentage 25% and CD4 cell count 500 cells/mL
(for children aged 7–15 years) were randomized 1:1 to either
continue antiretroviral therapy or undergo a CD4 cell–guided
PTI and were followed up for at least 72 weeks. This study was
approved by the ethics committees of all participating sites.
Children randomized to the PTI strategy and taking a reg-
imen that included an NNRTI and/or lamivudine stopped ther-
apy with either a staggered stop or a replacement stop strategy,
at the discretion of the pediatrician. The original protocol (23
June 2005) recommended that, for a staggered stop strategy,
treatment with the NNRTI should be stopped at randomization,
and treatment with the remaining 2 drugs should be continued
for 7 days. For a replacement stop strategy, the NNRTI should
be switched to a single or ritonavir-boosted protease inhibitor
and treatment with the 3 drugs should be continued for 7 days.
For either strategy, if the regimen contained lamivudine, there
was an option to switch lamivudine to an alternative NRTI with
a high genetic barrier to resistance and a short half-life prior
to continuing the dual-NRTI regimen. In February 2006, an
interim analysis showed that all 10 children who stopped treat-
ment with nevirapine had plasma concentrations !0.15 mg/L
at day 7, but at least 2 children had detectable concentrations
with use of a more sensitive assay (0.06 and 0.064 mg/L). Three
of 7 children who stopped efavirenz had detectable efavirenz
plasma concentrations at day 14. Therefore, the protocol was
amended (on 10 March 2006) to recommend a staggered stop
or replacement stop for 7–14 days for nevirapine and for at
least 14 days for efavirenz. Here, we present data for all children
in the PENTA-11 trial who stopped treatment with nevirapine-
or efavirenz-containing regimens during their first PTI. NNRTI
plasma drug concentrations and HIV-1 RNA load were mea-
sured at 0, 7 (drug concentrations only), 14, and 28 days after
stopping treatment with the NNRTI, and HIV-1 population
sequencing was performed in the first plasma sample with an
HIV load 1500 copies/mL.
Antiretroviral drug concentration assay. Nevirapine and
efavirenz plasma drug concentrations were measured by vali-
dated high-performance liquid chromatography methods, with
a lower limit of quantification of 0.05–0.25 mg/L for nevirapine
and 0.05–0.2 mg/L for efavirenz. For this analysis, a threshold
value for detection of 0.25 mg/L for nevirapine and 0.2
mg/L for efavirenz was used. All of the laboratories involved
in this study participate in International Quality Control Pro-
grams for antiretroviral drug measurements [8, 9].
HIV-1 resistance assay. HIV RNA population sequencing
was performed in local PENTA network laboratories. Viral nu-
cleic acid was extracted from plasma with use of Qiagen or
Roche systems, and the pol-gene PCR was amplified and se-
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Figure 1. Summary of randomization assignment, HAART regimens interrupted, and stopping strategies employed during the first planned treatment
interruption cycle for children enrolled in the Paediatric European Network for Treatment of AIDS 11: Treatment Interruption in Children with Chronic
HIV-Infection trial. ART, antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor.
quenced using ABI capillary sequencers (Applied Biosystems).
The minimum length of sequence covered all of the protease
gene and positions 38–250 in the reverse transcriptase. Inter-
pretation of mutations was undertaken using the Stanford Uni-
versity HIV database [10] or the AC11 National Agency for
AIDS Research (ANRS) algorithm [11].
Statistical analysis. Day 0 was defined as the day on which
treatment with the NNRTI was stopped; this was the day of
randomization for 12 children (34%) but ranged from 1 to 16
days after randomization for the remaining children because
of logistical issues. Baseline characteristics are given for the time
of randomization except for laboratory measurements, which
are those recorded nearest to (before or on) day 0. For the
virologic evaluations after treatment interruption, viral load
measurements recorded below a limit of detection of 150 cop-
ies/mL (e.g., !400 copies/mL) were assumed to be 150 copies/
mL.
RESULTS
Of the 110 children enrolled in PENTA-11 between November
2004 and December 2006, 56 were randomized to the PTI arm.
Of these children, 35 stopped treatment with an NNRTI-con-
taining HAART regimen: 20 stopped treatment with nevirapine,
and 15 stopped treatment with efavirenz (figure 1). Baseline
characteristics of children interrupting treatment with an
NNRTI are shown in table 1. Of note, at day 0, viral load was
50 copies/mL (range, 50–700 copies/mL) in 6 (17%) of the
children despite being stable at !50 copies/mL for the previous
6 months, up to and including the screening visit. Four of these
6 children followed a staggered stop strategy, and 2 followed a
replacement stop strategy.
Of the NNRTI-based regimens that were interrupted, 27
(77%) of 35 included lamivudine. A staggered stop strategy was
used for 11 (55%) of the children interrupting treatment with
nevirapine; lamivudine was included in 7 of these regimens,
and 2 children had lamivudine switched to didanosine for 1
week. All 9 children who stopped treatment with nevirapine
using a replacement stop strategy were receiving lamivudine; 6
children had lamivudine replaced with didanosine and had lo-
pinavir-ritonavir added to the regimen, and 3 children retained
lamivudine and had either lopinavir-ritonavir (2 children) or
nelfinavir (1 child) added to their regimen. Similarly, 10 (67%)
of 15 children interrupted treatment with efavirenz using a
staggered stop strategy; lamivudine was included in 8 of these
regimens, but only 1 child had lamivudine switched to dida-
nosine. Five children interrupted treatment with efavirenz with
a replacement stop strategy, and all had lopinavir-ritonavir
added to the regimen; lamivudine was included in 3 of these
regimens, and lamivudine was switched to didanosine for 1
child.
The median time from stopping treatment with the NNRTI
to stopping treatment with all drugs was 9 days (range, 6–15
days) for children receiving nevirapine and 14 days (range, 6–
18 days) for children receiving efavirenz. For the staggered stop
strategy, the median times were 8 days (range, 6–14 days) and
14 days (range, 6–18 days) for nevirapine and efavirenz, re-
spectively; 14 days (range, 6–15 days) was the median time for
a replacement stop strategy for both drugs.
NNRTI plasma drug concentrations after treatment
interruption. Plasma drug concentration data were available
for 19 children stopping treatment with nevirapine and 14 chil-
dren stopping treatment with efavirenz. The percentages of
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Table 1. Baseline demographic and clinical characteristics of children who interrupted treatment with
a nevirapine (NVP)– or efavirenz (EFV)–containing HAART regimen.
Variable
NVP group
(n p 20)
EFV group
(n p 15)
All patients
(n p 35)
Sex
Male 9 (45) 7 (47) 16 (46)
Female 11 (55) 8 (53) 19 (54)
Ethnicity
White 5 (25) 3 (20) 8 (23)
Black 5 (25) 6 (40) 11 (31)
Asian 8 (40) 3 (20) 11 (31)
Mixed 2 (10) 3 (20) 5 (14)
Age, median years (range) 8.3 (3.6–15.9) 9.4 (5.0–15.0) 8.9 (3.6–15.9)
HIV RNA level !50 copies/mL 17 (85) 11a (79) 28a (82)
CD4 cell count, median cells/mL (range) 1033b (531–2100) 919 (487–2646) 1026b (487–2646)
CD4 cell percentage, median % (range) 38b (29–53) 36 (24–42) 38b (24–53)
Previous ART exposure
All 3 main classes 5 (25) 5 (33) 10 (29)
NRTI plus NNRTI 15 (75) 10 (67) 25 (71)
ART drugs received, median no. (range)
All 3 main classes 4 (3–8) 4 (3–8) 4 (3–8)
NRTIs 2.5 (2–4) 3 (2–5) 3 (2–5)
NNRTIs 1 (1–2) 1 (1–2) 1 (1–2)
PIs 0 (0–3) 0 (0–2) 0 (0–3)
Cumulative ART exposure, median years (range)
All ART drugs 5.2 (1.7–15.3) 6.1 (2.7–10.8) 5.4 (1.7–15.3)
NRTIs 5.2 (1.7–11.6) 6.1 (2.7–10.8) 5.4 (1.7–11.6)
NNRTIs 4.0 (1.7–7.7) 3.7 (1.9–7.9) 3.7 (1.7–7.9)
PIs 0 (0–8.5) 0 (0–6.3) 0 (0–8.5)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Baseline characteristics are given at the time of random-
ization except for laboratory measurements, which are those measurements recorded nearest to or on (but not after) the day
on which the NNRTI was stopped (day 0). ART, antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor;
NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a Data on HIV RNA level at day 0 was unavailable for 1 child; percentages are for children with available data.
b CD4 cell count and CD4 cell percentage data at day 0 were unavailable for 1 child; percentages are for children with
available data.
children with nevirapine and efavirenz plasma concentrations
above the threshold at 0, 7, 14, and 28 days after treatment
with the NNRTI was stopped are shown in figure 2.
At the time of stopping treatment with nevirapine, the me-
dian nevirapine dose was 306 mg/m2 (range, 221–410 mg/m2),
and the plasma concentration was 7.0 mg/L (range, 2.2–15.1
mg/L) (3 children had plasma concentrations that were less
than the target therapeutic concentration of 3.0 mg/L [14]). Of
19 children, 1 child (whose plasma concentration at day 0 was
15.05 mg/L) had a nevirapine plasma concentration 10.25 mg/
L (1.31 mg/L) 7 days after stopping treatment with nevirapine,
which decreased to 0.12 mg/L by day 14 (lower limit of quan-
tification [LLOQ] of the assay was 0.05 mg/L; nevirapine con-
centrations were not measured for this child after day 14). Of
the 18 remaining children, 16 had samples assayed with a more
sensitive assay, 1 with an LLOQ of 0.15 mg/L, 6 with an LLOQ
of 0.10 mg/L, and 9 with an LLOQ of 0.05 mg/L. At 7 days,
5 children had nevirapine plasma concentrations above the
LLOQ for the assay but below 0.25 mg/L (0.057, 0.060, 0.060,
0.064, and 0.149 mg/L); of these children, 3 had nevirapine
concentrations 110.0 mg/L at day 0. At 14 days, no children
had a nevirapine concentration 10.25 mg/L, and only 1 child
had a detectable plasma concentration above the LLOQ for the
assay (described above).
The median efavirenz dose and median plasma drug con-
centration at treatment interruption were 12.3 mg/kg (range,
8.1–17.2 mg/kg) and 2.0 mg/L (range, 0.3–3.5 mg/L), respec-
tively, for 12 children, including 2 with plasma concentrations
less than the target therapeutic concentration of 1.0 mg/L [14].
Of 8 children, 4 had detectable efavirenz plasma concentrations
10.20 mg/L (0.40, 0.54, 0.61, and 4.07 mg/L) 7 days after stop-
ping treatment (time from stopping treatment with refavirenz
to stopping treatment with all drugs was 13, 18, 7, and 6 days,
respectively). Among the 4 remaining children, all had samples
 at K
atholieke U
niversiteit on N
ovem
ber 1, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
HIV/AIDS • CID 2008:46 (15 May) • 1605
Figure 2. Percentage of children with quantifiable plasma nonnucleo-
side reverse-transcriptase inhibitor concentrations at 0, 7, 14, and 28
days after interruption of a nevirapine (NVP)– or efavirenz (EFV)–containing
HAART regimen. The lower threshold of detection was 0.25 mg/L for
NVP and was 0.20 mg/L for EFV. The number of children with samples
available at each time point is reported above each bar.
assayed with a more sensitive assay (3 with an LLOQ of 0.05
mg/L and 1 with an LLOQ of 0.078 mg/L); 2 of these children
had efavirenz plasma concentrations above the LLOQ for the
assay but !0.20 mg/L at day 7 after stopping treatment (0.12
and 0.19 mg/L). The 2 children with the greatest efavirenz
plasma concentrations 10.20 mg/L at day 7 also had plasma
concentrations of 0.26 and 0.32 mg/L 14 days after interruption.
One additional child, for whom plasma concentrations were
not measured at day 7, had an efavirenz plasma concentration
of 0.29 mg/L 14 days after stopping efavirenz (time from stop-
ping efavirenz to stopping all drugs was 6 days). Two of the 3
children with detectable concentrations at day 14 were also
tested at day 28, and no efavirenz was detected.
Viral load rebound. At day 14, 6 (38%) of 16 and 2 (17%)
of 12 children interrupting treatment with nevirapine and efa-
virenz, respectively, had viral loads 50 copies/mL (range for
the nevirapine group, 52–7000 copies/mL; range for the efa-
virenz group, 120–1600 copies/mL), which increased to 19
(95%) of 20 and 12 (92%) of 13 by day 28 (range for the
nevirapine group, 300–4,897,788 copies/mL; range for the efa-
virenz group, !100 to 147,000 copies/mL) (table 2).
NNRTI resistance. HIV genotyping was performed at var-
ious times during the first 3 months after interruption of treat-
ment with an NNRTI, depending on viral load values (for 1
child at week 2, 21 children at week 4, 10 children at week 8,
and 2 children at week 12). For 1 child, cDNA could not be
amplified. No new NNRTI resistance mutations were detected
in virus from the 35 children interrupting treatment with an
NNRTI-containing HAART regimen. One child who was re-
ceiving nevirapine had the NNRTI resistance mutation K103N
detected 14 days after stopping treatment with nevirapine, but
this child had a viral load of 700 copies/mL at day 0 (!50
copies/mL at the screening visit), and the K103N resistance
mutation could also be detected in virus isolated from a stored
sample taken at day 0. No lamivudine-associated resistance
mutations were detected in virus obtained from any of the
children.
DISCUSSION
In this substudy of virologically suppressed HIV-infected chil-
dren enrolled in PENTA-11 trial and undergoing a PTI, we
found that nevirapine and efavirenz plasma drug concentra-
tions were below the detection threshold in the majority of
children at 1 week (for those stopping treatment with nevi-
rapine) and 2 weeks (for those stopping treatment with efa-
virenz) after treatment interruption and were below the lower
limit of detection for all children at 2 weeks (for those stopping
treatment with nevirapine) and 4 weeks (for those stopping
treatment with efavirenz). No new NNRTI or lamivudine re-
sistance mutations were detected.
We observed that efavirenz persisted longer than nevirapine
in plasma. This result was apparent early in the trial, and we
changed the management strategy to recommend staggered
stop or replacement stop of efavirenz for 14 days rather than
7 days. At this time, a 7–14-day staggered stop strategy was
recommended for children stopping treatment with nevirapine.
The final analysis confirmed that efavirenz had longer persis-
tence, an observation that was consistent with reports involving
adults. For example, in a report describing 8 adults who in-
terrupted treatment with efavirenz, median plasma concentra-
tions were 0.31, 0.15, and 0.06 mg/L at 7, 14, and 21 days,
respectively [3]. In a substudy of the Development of Antiret-
roviral Therapy in Africa (DART) trial, in which adults inter-
rupted treatment with nevirapine using a 1-week staggered stop
strategy, 5 (28%) of 18 patients had nevirapine concentrations
10.2 mg/L at 7 days, decreasing to only 1 (5%) of 19 patients
by day 14 [4].
In our study, a staggered stop or replacement stop of 6–18
days (median duration, 14 days) was used for children inter-
rupting treatment with efavirenz, and no new NNRTI resistance
selection was observed as viral load increased. Despite this, the
high percentage of children with efavirenz concentrations10.20
mg/L at 14 days, coupled with the persistence of efavirenz for
3 weeks [3] and sometimes longer in adults [12], would suggest
that a staggered stop or replacement stop duration 114 days
should be advocated. The authors of the DART substudy sug-
gest that a 7–10-day staggered stop strategy is adequate for
African patients discontinuing treatment with nevirapine, for
whom protease inhibitor replacement is not feasible. In our
study, a staggered stop or replacement stop of 6–15 days (me-
dian duration, 9 days) was used for children interrupting treat-
ment with nevirapine, and no NNRTI resistance was found. Of
interest, whereas median nevirapine concentrations at treat-
ment interruption were similar in our study and the DART
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Table 2. Proportion (%) of children with HIV RNA load 50 copies/mL at 0, 14, and 28 days after
interrupting a nevirapine- or efavirenz-containing HAART regimen with use of either a staggered stop
(SS) or replacement stop (RS) strategy.
Treatment interruption strategy
Nevirapine group Efavirenz group
Day 0 Day 14 Day 28 Day 0 Day 14 Day 28
SS and RS 3/20 (15) 6/16 (38) 19/20 (95) 3/14 (21) 2/12 (17) 12/13 (92)
SS 2/11 (18) 3/9 (33) 11/11 (100) 2/10 (20) 2/7 (29) 8/8 (100)
RS 1/9 (11) 3/7 (43) 8/9 (89) 1/4 (25) 0/5 (0) 4/5 (80)
study, concentrations 7 days after treatment interruption were
generally higher in the adults participating in the DART study
than in children participating in the PENTA-11 trial, possibly
because of higher nevirapine clearance in the children.
A single-nucleotide polymorphism in the gene of the cyto-
chrome P450 2B6 isoenzyme (CYP2B6 G516T) can reduce the
oral clearance of efavirenz and, possibly, nevirapine [13, 14];
therefore, patients carrying the homozygous variant genotype
may have a higher risk of selecting for NNRTI-resistant infec-
tion after treatment interruption. Indeed, predicted efavirenz
plasma exposure after treatment interruption was found to be
longer with the variant genotypes, suggesting that it may be
difficult to develop a standard stopping strategy [15]. Our study
did not include investigations of CYP2B6, although it would
be expected that part of interpatient variability could be at-
tributable to such polymorphisms.
It was not possible to compare the impact of the stopping
strategies on viral load rebound with adjustment for the time
between NNRTI treatment interruption and interruption of
treatment with the other drugs, because this varied considerably
among clinical sites, drug combinations, and strategies. For
example, to maximize safety for children, some sites conducted
real-time drug concentration assessments and stopped treat-
ment with all drugs only when NNRTIs were undetectable.
However, there is nothing in our observations that would favor
one strategy over another, although a longer replacement stop
strategy may be preferred over a longer staggered stop strategy
to avoid the development of NRTI-resistant infection as the
result of dual-NRTI therapy.
Comparing the persistence of NNRTIs between studies can
be difficult because of the different LLOQs used. This raises
the issue of drug concentration thresholds at which one expects
an increased risk of selection of drug-resistant viruses. On the
basis of the inhibitory concentration at which 50% of isolates
are susceptible to nevirapine (0.01–0.02 mg/L), targeting a
threshold lower than the 0.25 mg/L used in our study may have
been preferable. However, although nevirapine plasma concen-
trations were barely detectable at 7 and 14 days (range, 0.05–
0.25 mg/L) with use of the more sensitive assay, it appears that
such very low concentrations were insufficient to induce se-
lection of HIV resistance mutations. Indeed, with the stopping
strategies used, significant viral load rebound did not appear
until 14 days after stopping treatment with nevirapine.
Although no NNRTI resistance was detected using popula-
tion sequencing techniques, minor resistant viral populations
may have been selected and could have been detected using
more-sensitive assays (e.g., Oligonucleotide-ligation [16],
LigAmp [17] or Allele Specific-PCR [18]). Also, resistance mu-
tations outside the DNA polymerase domain of HIV reverse
transcriptase (i.e., connection and RNAse H domains) were not
assessed but have recently been suggested to confer resistance
to nevirapine [19]; however, the long-term clinical impact of
such mutations and the minor populations of NNRTI-resistant
viruses are uncertain.
Concerns regarding the selection of NNRTI resistance mu-
tations after treatment interruption were originally raised with
the use of single-dose nevirapine during labor for the preven-
tion of mother-to-child transmission of HIV. Depending on
the background prophylaxis regimen, the sensitivity of the re-
sistance test, and the virus subtype, NNRTI resistance mutations
have been detected in 20%–70% of women who received single-
dose nevirapine [20, 21], and these mutations have proved to
impact the success of subsequent NNRTI-based therapies, in
particular when initiated within months of exposure [6]. How-
ever, viral loads in women at the time of single-dose nevirapine
exposure are expected to be much higher than viral loads in
children or adults receiving long-term nevirapine-based
HAART with undetectable viral loads who undergo a PTI. Also,
autoinduction of nevirapine clearance in patients receiving
HAART results in a shortened half-life. As a consequence, the
risk of selecting NNRTI-resistant viruses as part of a PTI is
expected to be lower than that observed in the prevention of
mother-to-child transmission of HIV setting.
In conclusion, in virologically suppressed children who in-
terrupt an NNRTI-based HAART regimen during their first
PTI cycle, the adoption in this trial of a staggered stop or
replacement stop strategy for a median duration of 9 days for
nevirapine and 14 days for efavirenz was not associated with
the selection of drug resistance mutations. Whether a replace-
ment stop or staggered stop is preferable could not be deter-
mined, although there are theoretical reasons to prefer a re-
placement stop strategy, particularly for efavirenz, which
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persists longer than nevirapine. However, our data are consis-
tent with other studies in which a staggered stop strategy for
nevirapine appeared to be adequate. We are continuing to mon-
itor HIV load, drug resistance, and drug concentrations in chil-
dren who undergo subsequent PTIs.
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